Tesla Revives Dojo Supercomputer Project With AI5 Chip at the Core 
BHP Posts Record Iron Ore Output as China Pricing Pressures Loom 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
HKEX’s Permissive IPO Rules Could Open Opportunities for Korea to Strengthen Its Position in International Listings 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Laquinimod
- The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
- The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
- The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
- Orphan Drug Designation granted for laquinimod for the treatment of Huntington's disease by the US Food and Drug Administration (FDA)
ANYARA
- Project proceeding according to plan
Tasquinimod, paquinimod and SILC
- Out-licensing activities are continuing
- The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
- Orphan Drug Designation granted for tasquinimod for the treatment of multiple myeloma by the US Food and Drug Administration (FDA)
- Product patent for SILC substances granted by the European Patent Office
Financial summary
| SEK M | Jan.-Mar. | Full-year | ||
| 2017 | 2016 | 2016 | ||
| Net sales | 4.7 | 3.9 | 19.0 | |
| Operating loss | -14.6 | -16.1 | -55.1 | |
| Loss after tax | -15.8 | -16.8 | -59.6 | |
| Loss per share, before and after dilution (SEK) | -0.16 | -0.19 | -0.65 | |
| Cash and cash equivalents (at close of period) | 62.7 | 76.5 | 77.7 | |
- Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017
For further information, please contact:
| Tomas Leanderson, President and CEO Tel: +46 (0) 46 19 20 95 Hans Kolam, CFO Tel: +46 (0)46 19 20 44 | Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 (0)46-19 20 00 |
The report is also available at www.activebiotech.com.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/e19e9aad-c392-4cf4-b127-da952a463a0f
